NCT07601841

Brief Summary

This is a clinical trial designed to examine how improved sleep through morning bright light therapy is improving downstream key physiologic processes related to brain health, i.e., mitochondrial function, systemic inflammation, and glymphatic function. All proposed methodology is already approved in other IRB applications.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for not_applicable

Timeline
53mo left

Started Dec 2025

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress9%
Dec 2025Sep 2030

Study Start

First participant enrolled

December 12, 2025

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

April 28, 2026

Completed
24 days until next milestone

First Posted

Study publicly available on registry

May 22, 2026

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 12, 2028

Expected
1.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2030

Last Updated

May 22, 2026

Status Verified

May 1, 2026

Enrollment Period

3 years

First QC Date

April 28, 2026

Last Update Submit

May 18, 2026

Conditions

Outcome Measures

Primary Outcomes (3)

  • Define the profile of blood-based markers of systemic inflammation pre- vs post-MBLT.

    The primary outcome defines the pre- to post-intervention change in inflammatory target expression using NULISA proteomics (reporting proteins as NPQ relative units).

    From pre-intervention to end of device use (Approximately 4 weeks).

  • Define mitochondrial function (oxygen consumption rate via Seahorse) pre- vs. post-MBLT.

    The primary outcome of this aim reflects pre- to post-intervention change in mitochondrial bioenergetics. Specific metrics include basal oxygen consumption rate, maximal oxygen consumption rate, and spare/reserve capacity (difference between maximal and basal oxygen consumption rate).

    From pre-intervention to end of device use (Approximately 4 weeks).

  • Explore glymphatic function via novel multi-model non-contrast-based MRI pre- vs. post-MBLT.

    The primary outcome defines pre- to post-intervention change in MRI visibler perivascular space burden (PVS number/volume).

    From pre-intervention to end of device use (Approximately 4 weeks).

Study Arms (2)

Morning Bright Light Therapy

EXPERIMENTAL

Exposure to bright light in the morning every day for an hour for 4 weeks.

Device: Morning Bright Light Therapy

Negative Ion Generator Therapy

OTHER

Exposure to negative ions in the morning every day for an hour for 4 weeks.

Device: Negative Ion Generator Therapy

Interventions

Exposure to bright light shortly after waking.

Also known as: MBLT
Morning Bright Light Therapy

Exposure to negative ions shortly after waking.

Negative Ion Generator Therapy

Eligibility Criteria

Age18 Years - 89 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
All subjects must: 1. Male and female; any race; 18-89 years of age. 2. Be English speaking.\* 3. Be accessible via phone. 4. Be non-decisionally impaired. Determined by assessing the subject's ability to verbalize their understanding of the protocol back to us during the informed consent process. 5. Not have a history of macular degeneration. 6. Not have a history of bipolar disorder. 7. Not be currently using a lightbox or a negative ion generator. 8. Not be a shift worker. 9. Have a documented history of TBI via the Head Trauma Events Characteristics (HTEC) or OHIO conducted in accordance with VA/DoD Clinical Practice Guidelines.88 10. Present with self-reported sleep-wake disturbances. 11. Remain clinically stable for current pharmacologic treatment related to depression/anxiety, sleep, and pain. 12. MRI specific compatibility requirements: * No pacemaker, wires, defribrillator or implanted heart valves * No history of head surgery requiring aneurysm clips * No history of other orthopedic or general surgery requiring the implantation of ferrous pins, joints, electric devices/pumps, or other foreign metal objects * History of eye exposure to metal (unprotected welding/metalworking/shrapnel) is allowable provided the participant screens negative for metal in the eyes on an orbital x-ray or is able to provide clinical documentation of having screened negative. * No history of non-removable hearing aids, middle/inner ear prosthesis, or dentures * No history of claustrophobia; if unsure participant will be pre-screened in our mock scanner * Not currently pregnant, breastfeeding, or have an implanted IUD. Participants who are unsure of their pregnancy status will be administered an hCG urine pregnancy test the day of their scan. * Able to lay flat on their back comfortably without a thick pillow for an extended period of time. * Shoulder width does not exceed width for safety fitting in the MRI bore. * This study is limited to English-speaking participants because all assessments, interventions, and consent materials are currently validated and approved only in English. Expanding to other languages would require translation and psychometric validation, which are beyond the scope and budget of this study. This limitation is acknowledged and will be addressed in future research as resources permit. Finally, the study team is only fluent in English, making it infeasible to accurately consent or interact with non-English speakers without interpreting services which again is outside of the scope of this projects budget and timeline. Proceeding without formal translation services would risk miscommunication in informed consent, data collection, or participant support and thus protects participants informed consent and participant understanding.

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Study Sites (1)

Oregon Health and Science University

Portland, Oregon, 97239, United States

RECRUITING

MeSH Terms

Conditions

Brain Injuries, TraumaticInflammation

Condition Hierarchy (Ancestors)

Brain InjuriesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesCraniocerebral TraumaTrauma, Nervous SystemWounds and InjuriesPathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

Jonathan Elliott, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

April 28, 2026

First Posted

May 22, 2026

Study Start

December 12, 2025

Primary Completion (Estimated)

December 12, 2028

Study Completion (Estimated)

September 30, 2030

Last Updated

May 22, 2026

Record last verified: 2026-05

Locations